Investigation For Maximal Peyronie's Reduction Efficacy And Safety Studies (IMPRESS) Articles

Articles

  • Collagenase Clostridium Histolyticum in the Treatment of Urologic Disease: Current and Future Impact: Beyond the Abstract

    Intralesional injection of collagenase clostridium histolyticum (CCH) has become the gold standard for minimally invasive treatment of stable phase Peyronie’s disease (PD).  Through years of well-designed clinical trials and post-approval studies involving over 1,500 patients, CCH continues to demonstrate clinical efficacy by decreasing penile curvature and plaque consistency, as well as improving sexual function and quality of life in patients with PD [1-5].
    Published July 10, 2017
  • Evidence supports efficacy of enzyme in treatment of Peyronie's disease

    SAN DIEGO, CA USA (Press Release) - May 6, 2013 - According to data from the Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies (IMPRESS) I and II phase three trials, men who received injectable treatments of collagenase clostridium histolyticum (CCH), an enzyme that breaks down fibrous scar tissue, showed improvement in both penile curvature deformity and Peyronie’s disease symptom bother.

    Published May 6, 2013